<DOC>
	<DOCNO>NCT00873756</DOCNO>
	<brief_summary>This multicenter , open-label study enrol total 23 patient .</brief_summary>
	<brief_title>A Study Dulanermin Administered Combination With FOLFOX Regimen Bevacizumab Patients With Previously Untreated , Locally Advanced , Recurrent , Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Histologically confirm CRC evidence locally advanced recurrent metastatic disease ( i.e. , radiographic image biopsy ) measurable tumor lesion Life expectancy &gt; 3 month For patient reproductive potential ( male female ) , use reliable mean contraception throughout trial Willingness capability accessible study followup Prior 5FU , capecitabine , and/or oxaliplatin treatment exception : prior oxaliplatin treatment = &lt; 6 week advance metastatic setting ; prior treatment 5FU , capecitabine , and/or oxaliplatin adjuvant set relapse occur &gt; 6 month conclude adjuvant therapy Peripheral neuropathy Grade &gt; = 2 Prior radiotherapy measurable metastatic lesion ( ) use response assessment , unless lesion progress subsequent radiotherapy Radiotherapy peripheral lesion within 14 day prior Cycle 1 , Day 1 , radiotherapy thoracic , abdominal , pelvic field within 28 day prior Cycle 1 , Day 1 Chemotherapy , hormonal therapy , immunotherapy within 4 week prior Cycle 1 , Day 1 Evidence clinically detectable ascites Other invasive malignancy within 5 year prior Cycle 1 , Day 1 Current recent participation another experimental drug study Clinically significant cardiovascular disease , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia within 1 year prior Cycle 1 , Day 1 , Grade II great peripheral vascular disease Cycle 1 , Day 1 Active infection require parenteral antibiotic Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Cycle 1 , Day 1 , fine needle aspiration minor surgery ( port placement ) within 7 day prior Cycle 1 , Day 1 , anticipation need major surgical procedure course study Known suspect positive human immunodeficiency virus ( HIV ) Known positive hepatitis C hepatitis B surface antigen History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug specify study treatment , might affect interpretation result study render patient high risk treatment complication Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy History arterial thromboembolic event 6 month prior Cycle 1 , Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Cycle 1 , Day 1 Bleeding diathesis coagulopathy Pregnancy ( positive pregnancy test ) breast feed Serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CRC</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Avastin</keyword>
	<keyword>Apo2L/TRAIL</keyword>
</DOC>